Kosan Names Pieter Timmermans Senior Vice President, Preclinical Development
Thursday February 3, 2:00 pm ET
HAYWARD, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN - News) announced today that it has appointed Pieter Timmermans, Ph.D. Senior Vice President, Preclinical Development.
Dr. Timmermans brings more than 20 years of pharmaceutical and biotechnology experience to Kosan, most recently serving as Vice President, Pharmacology and Preclinical Development at Amgen Inc. subsequent to its acquisition of Tularik Inc. From 1997 to 2004, Dr. Timmermans held the same position at Tularik and built Tularik's preclinical department. Previously, he served in various management positions at The DuPont Merck Pharmaceutical Company and E.I. du Pont de Nemours & Company. He also was Associate Professor in Pharmacology at the University of Amsterdam. The author of more than 580 scientific publications, Dr. Timmermans holds a Ph.D. in molecular pharmacology and a B.S. in chemistry, mathematics, physics and biology from Leiden State University.
"We are absolutely delighted that Pieter has chosen to join the Kosan development team. Pieter's broad expertise in pharmacology and preclinical drug development will be invaluable as we continue to build our preclinical department and advance our strong preclinical polyketide pipeline, including drug candidates for cancer, gastrointestinal disorders and infectious disease into the clinic," said Robert G. Johnson, Jr., M.D., Ph.D., Executive Vice President, Development and Chief Medical Officer, Kosan Biosciences. |
